122957-33-9Relevant articles and documents
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists
Curtin, Michael L.,Davidsen, Steven K.,Heyman, H. Robin,Garland, Robert B.,Sheppard, George S.,Florjancic, Alan S.,Xu, Lianhong,Carrera Jr., George M.,Steinman, Douglas H.,Trautmann, Jeff A.,Albert, Daniel H.,Magoc, Terrance J.,Tapang, Paul,Rhein, David A.,Conway, Richard G.,Luo, Gongjin,Denissen, Jon F.,Marsh, Kennan C.,Morgan, Douglas W.,Summers, James B.
, p. 74 - 95 (2007/10/03)
Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal m
1,4-dihydropyridines useful as pharmaceuticals
-
, (2008/06/13)
The invention provides compounds of the formula: STR1 The variables are defined in the specification. The compounds are useful e.g. for the curative or prophylactic treatment of allergic conditions.
1,4-dihydropyridine derivatives
-
, (2008/06/13)
The invention provides compounds of the formula STR1 and pharmaceutically acceptable salts thereof, wherein R is phenyl substituted by halo; R1 is C1 -C4 alkyl; is hydrogen, C5 -C7 cycloalkyl, benzyl